FDA to review ublituximab with umbralisib for chronic lymphocytic leukaemia and small lymphocytic lymphoma

The submission for regulatory review of this combination of an anti-CD20 monoclonal antibody (ublituximab) and a PI3K-delta and CK1-epsilon inhibitor (umbralisib) was based mainly on data from the UNITY-CLL trial.

Source:

Biospace Inc.